Advanced search
Publication Cover
Leukemia & Lymphoma Volume 32, 1998 - Issue 1-2
Submit an article Journal homepage
20
Views
2
CrossRef citations to date
0
Altmetric
Original Article

Ninety-Six-Hour Paclitaxel Infusion with Mitoxantrone and Ifosfamide/Mesna and Consolidation with ESHAP for Refractory and Relapsed Non-Hodgkin's Lymphoma

J. E. Romaguera Department of Hematology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, 77030, USA
,
F. B. Hagemeister Department of Hematology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, 77030, USA
,
P. McLaughlin Department of Hematology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, 77030, USA
,
M. A. Rodriguez Department of Hematology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, 77030, USA
,
C. Bachier Department of Hematology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, 77030, USA
,
H. Preti Department of Hematology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, 77030, USA
,
A. H. Sarris Department of Hematology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, 77030, USA
,
D. Weber Department of Hematology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, 77030, USA
,
A. Younes Department of Hematology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, 77030, USA
&
F. Cabanillas Department of Hematology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, 77030, USA
 show all
Pages 97-106 | Received 20 Mar 1998, Published online: 01 Jul 2009

References

  • McGuire W P, Rowinsky E K. Taxol: a novel investigational Agent. Jo Natlo Cancer Insto. 1990; 82: 1247–1259
  • Younes A, Ayoub J P, Sards A H, Hagemiester F B, North L, Pate O, McLuaghlin P, Rodriguez M A, Romaguera J E, Kurzrock R, Preti A, Bachier C, Smith T, Cabanillas F. Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial. Br. J. Haematol. 1997; 96: 328–332
  • Younes A, Preti A, Romaguera J E, North L, Mesina O, Hage-Meister F B, Sarris A, McLaughlin P, Rodriguez M A, Cabanillas F. Activity of Taxol and high dose Cytoxan with granulocyte colony-stimulating factor (G-CSF) in 54 patients with relapsed/refractory non-Hodgkin's lymphoma (NHL). Proceedings of American Society of Clinical Oncology 1997; 16: 21a, abstract no. 74
  • Ahmed T, Lake D, Seiter Km Kancherla R, Blechman I, Durrani H, Feldman E J, Madden R. Phase II study of Taxol and etoposide in relapsed/refractory lymphoma. Proceedings of American Society of Clinical Oncology 1997; 16: 33a, abstract # 116
  • Cabanillas F, Hagemeister F B, Riggs S, Salvador P, Velasquez W, McLaughlin P. Results of Ifosfa-mide-Etoposide salvage combinations for patients with recurrent or refractory aggressive lymphoma. Malignant Lymphomas and Hodgkin's Disease: Experimental and Therapeutic Advances, F. Cavalli, G. Bonadonna, M. Roze-Neweig. Marinus Nijhoff Publishing, Boston 1985; 485–492
  • Cabanillas F, Hagemeister F B, McLaughlin P, Velasquez W, Riggs S, Fuller L, Smith T. Results of MIME salvage regimen for recurrent or refractory lymphoma. J. Clin. Oncol. 1987; 5: 407–412
  • Velasquez W S, Mc Laughlin P, Tucker S, Hagemeister F B, Swan F, Rodriguez M A, Romaguera J E, Rubenstein E, Cabanillas F. ESHAP-An effective chemotherapy regimen in refractory and relapsing lymphoma. A 4-year follow-up. J. Clin. Oncol. 1994; 12: 1169–1176
  • Hahn S M, Liebmann J E, Goldspiel B R, Mitchell J, Kaufman D. Taxol in combination with doxorubicin, etoposide, and m-AMSA: Possible antagonism in vitro. Proceedings of the American Association of Cancer Reserach 1992; 33: 41
  • Wilson W H, Berg S, Bryan G, Wittes R, Bates S, Fojo A, Steinberg S M, Goldspiel B R, Herdt J, O'Shaughnessy J, et al. Phase I/TI study of Taxol 96-hr infusion in refractory lymphoma and breast cancer: pharmacodynamics and analysis of multiple drug resistance. Proceedings of the American Society of Clinical Oncology 1993; 134, abstract no. 335, 1993
  • Rodriguez M A, Cabanillas F, Velasquez W, Hagemiste F B, McLaughlin P, Swan F, Romaguera J E. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J. Clin. Oncol. 1995; 13: 1734–1741
  • Harris N L, Jaffe E S, Stein H, Banks P M, Chan J K, Cleary M L, Delsol G, De Wolf-Peeters C, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392
  • Stanley K E. Prognostic factors for survival in patients with inoperable lung cancer. J. Natl. Cancer Inst. 1980; 65: 25–32
  • Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc 1972; 35: 185–207
  • Kaplan E L, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481
  • Swan F, Velasquez W, Tucker S, Redman J R, Rodriguez M A, McLaughlin P, Hagemeister F B, Cabanillas F. A new serologic staging system for large cell lymphomas based on initial B2 microglobulin and lactate dehydrogenase levels. J. Clin. Oncol. 1989; 7: 1518–1527
  • Younes A, Ayoub J P, Hagemeister F B, McLaughlin P, Sarris A, Rodriguez M A, Swan F, Romaguera J E, Martin J, Cabanillas F. No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to three-hour infusion schedule. J. Clin. Oncol. 1996; 14: 543–548
  • Wilson W H, Chabner B A, Bryant G, Bates S, Fojo A, Regis J, Jaffe E S, Steinberg S M, Goldspiel B R, Cheson B D, et al. Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas. J. Clin. Oncol. 1995; 13: 381–386

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.